Sugi Predict

Sugi Predict / Compounds / SCHEMBL1674134

SCHEMBL1674134

SCHEMBL1674134

CN(C)S(=O)(=O)c1cccc(B2OC(C)(C)C(C)(C)O2)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 3/20 0.44
▸ NPC1 O15118 2/20 0.44
▸ TNF P01375 1/20 0.44
▸ NOD1 Q9Y239 1/20 0.44
▸ LIPG Q9Y5X9 5/20 0.43
▸ LPL P06858 4/20 0.43
▸ ALDH1A1 P00352 5/20 0.43
▸ CA1 P00915 4/20 0.43
▸ CA2 P00918 4/20 0.43
▸ CA9 Q16790 4/20 0.43
▸ MEN1 O00255 4/20 0.40
▸ KMT2A Q03164 4/20 0.40
▸ LOX P28300 1/20 0.40
▸ CA12 O43570 1/20 0.40
▸ CA3 P07451 1/20 0.40
▸ CA4 P22748 1/20 0.40
▸ CA6 P23280 1/20 0.40
▸ CA5A P35218 1/20 0.40
▸ CA7 P43166 1/20 0.40
▸ CA14 Q9ULX7 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30510865 1.00 RAB9A (0.44) RAB9ANPC1TNFNOD1LIPG
SCHEMBL24365872 0.84 LIPG (0.46) LIPGLPLCA1CA2CA9
SCHEMBL15550950 0.84 ALDH1A1 (0.55) RAB9ALIPGLPLALDH1A1CA1
SCHEMBL30015709 0.83 LIPG (0.47) LIPGLPLCA1CA2CA9
SCHEMBL3754376 0.83 LIPG (0.47) LIPGLPLCA1CA2CA9
SCHEMBL182781 0.81 CA2 (0.60) LIPGLPLCA1CA2CA9
SCHEMBL31194545 0.81 SMN1; SMN2 (0.41) NPC1LIPGLPLALDH1A1CA1
SCHEMBL183232 0.81 CA1 (0.51) LIPGLPLALDH1A1CA1CA2
SCHEMBL18113963 0.81 CASP3 (0.47) LIPGLPLALDH1A1CA1CA2
SCHEMBL14719268 0.80 LIPG (0.51) LIPGLPLCA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060052396-A1 Arylamines for the treatment of conditions associated with gsk-3 ASTRAZENECA (SE) 2006-03-09 — — US claimed
CN-1551869-A Novel compound — 2004-12-01 — — CN claimed
EP-1414801-A1 ARYLAMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 AstraZeneca AB (SE) 2004-05-06 — — EP claimed
WO-2003004472-A1 ARYLAMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 ASTRAZENECA AB (SE) 2003-01-16 — — WO claimed
EP-3768675-B1 NOVEL TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME YUHAN CORP (KR) 2026-04-01 — — EP disclosed
US-20250352550-A1 SUBSTITUTED FUROPYRIDINES FOR THERAPEUTIC USE UNIV MASARYKOVA (CZ) 2025-11-20 — — US disclosed
US-20250066308-A1 BICYCLIC FUSED RING DERIVATIVE OR SALT THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME YUHAN CORPORATION (KR) 2025-02-27 — — US disclosed
US-20240417392-A1 3,3-DIFLUOROALLYLAMINES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME YUHAN CORP (KR) 2024-12-19 — — US disclosed
EP-4397655-A1 BICYCLIC FUSED RING DERIVATIVE OR SALT THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME Yuhan Corporation (KR) 2024-07-10 — — EP disclosed
WO-2024078649-A1 SUBSTITUTED FUROPYRIDINES FOR THERAPEUTIC USE MASARYKOVA UNIVERZITA (CZ) 2024-04-18 — — WO disclosed
EP-4353727-A1 SUBSTITUTED FUROPYRIDINES FOR THERAPEUTIC USE Masarykova Univerzita (CZ) 2024-04-17 — — EP disclosed
US-20230349907-A1 BIOPROBES FOR LYSYL OXIDASES AND USES THEREOF PHARMAXIS LTD. (AU) 2023-11-02 — — US disclosed
US-8354408-B2 N-containing heterocyclic compounds YM BIOSCIENCES AUSTRALIA PTY LTD (AU) 2013-01-15 — — US disclosed
US-20110092499-A1 N-CONTAINING HETEROCYCLIC COMPOUNDS YM BIOSCIENCES AUSTRALIA PTY LTD (AU) 2011-04-21 — — US disclosed
EP-2215094-A1 N-CONTAINING HETEROCYCLIC COMPOUNDS YM BioSciences Australia Pty Ltd (AU) 2010-08-11 — — EP disclosed
WO-2009062258-A1 N-CONTAINING HETEROCYCLIC COMPOUNDS CYTOPIA RESEARCH PTY LTD (AU) 2009-05-22 — — WO disclosed
US-20060052396-A1 Arylamines for the treatment of conditions associated with gsk-3 ASTRAZENECA (SE) 2006-03-09 — — US disclosed
CN-1551869-A Novel compound — 2004-12-01 — — CN disclosed
EP-1414801-A1 ARYLAMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 AstraZeneca AB (SE) 2004-05-06 — — EP disclosed
WO-2003004472-A1 ARYLAMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 ASTRAZENECA AB (SE) 2003-01-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250066308-A1 BICYCLIC FUSED RING DERIVATIVE OR SALT THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME LOX, XDH, IL4I1 RAB9A 1278/4885NPC1 737/4885TNF 3794/4885
US-20250352550-A1 SUBSTITUTED FUROPYRIDINES FOR THERAPEUTIC USE FLT3, ROS1, MAP4K2 RAB9A 2819/4885NPC1 4399/4885TNF 4739/4885
US-20230349907-A1 BIOPROBES FOR LYSYL OXIDASES AND USES THEREOF MAOB, LOX, LPO RAB9A 4236/4885NPC1 4426/4885TNF 4801/4885
US-20240417392-A1 3,3-DIFLUOROALLYLAMINES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME VAPA, VAPB, SLC10A1 RAB9A 1157/4885NPC1 6/4885TNF 4037/4885
US-20110092499-A1 N-CONTAINING HETEROCYCLIC COMPOUNDS JAK2, JAK3, JAK1 RAB9A 3353/4885NPC1 3357/4885TNF 1370/4885
US-20060052396-A1 Arylamines for the treatment of conditions associated with gsk-3 GSK3A, GSK3B, PYGL RAB9A 859/4885NPC1 784/4885TNF 3908/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.